Dow Jones Sustainability Index Again Recognizes Abbott
Abbott - the global health care company - was named to the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the third consecutive year. This selection recognizes Abbott's continued leadership in business, environmental and social performance.
Read more ...
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.
Read more ...
CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in cancer pain
CeNeS Pharmaceuticals plc (AIM: CEN) and the ERGOMED Group today announced that they have initiated recruitment into a Phase II study of the potential new pain drug CNS 5161. CNS 5161 is being developed under a co-development deal signed in July 2006 between CeNeS and ERGOMED.
Read more ...
AstraZeneca and Pozen To Start Phase III Trials With PN400
AstraZeneca announced today that it will start a Phase III programme for PN400, a new pain product under co-development with POZEN, Inc. The Phase III programme is scheduled to begin in 3Q 2007, with a US submission currently targeted for 1H 2009.
Read more ...
Bayer intends to delist from the New York Stock Exchange
Bayer AG intends to file for delisting of its American Depositary Shares (ADSs) from the New York Stock Exchange (NYSE). It is also planned to deregister with the U.S. Securities and Exchange Commission (SEC) and thereby terminate the respective reporting obligations.
Read more ...
Novartis to defend its intellectual property rights for Famvir®
Novartis will keep defending its intellectual property rights for the antiviral medicine Famvir®, which has various US patents valid until 2015, after a competitor company launched its own generic version in the United States.
Read more ...
Boehringer Ingelheim announce major global strategic alliance in novel nanobody® therapeutics
Boehringer Ingelheim and Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, today jointly announced a major global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics.
Read more ...